These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30427188)

  • 21. Observations on the Effects of Residualization and Dehalogenation on the Utility of
    Chitneni SK; Koumarianou E; Vaidyanathan G; Zalutsky MR
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31671554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.
    Feng Y; Sarrett SM; Meshaw RL; Vaidyanathan G; Cornejo MA; Zeglis BM; Zalutsky MR
    J Med Chem; 2022 Nov; 65(22):15358-15373. PubMed ID: 36368007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Efficacy of
    Dekempeneer Y; Caveliers V; Ooms M; Maertens D; Gysemans M; Lahoutte T; Xavier C; Lecocq Q; Maes K; Covens P; Miller BW; Bruchertseifer F; Morgenstern A; Cardinaels T; D'Huyvetter M
    Mol Pharm; 2020 Sep; 17(9):3553-3566. PubMed ID: 32787284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).
    Vaidyanathan G; Affleck DJ; Li J; Welsh P; Zalutsky MR
    Bioconjug Chem; 2001; 12(3):428-38. PubMed ID: 11353542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fully automated
    Nagachinta S; Novelli P; Joyard Y; Maindron N; Riss P; Dammicco S
    Sci Rep; 2022 Nov; 12(1):18655. PubMed ID: 36333403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
    Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
    Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography.
    Jahan M; Nag S; Krasikova R; Weber U; Muhs A; Pfeifer A; Spenger C; Willbold D; Gulyás B; Halldin C
    Nucl Med Biol; 2012 Apr; 39(3):315-23. PubMed ID: 22136889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET.
    Mume E; Orlova A; Malmström PU; Lundqvist H; Sjöberg S; Tolmachev V
    Nucl Med Biol; 2005 Aug; 32(6):613-22. PubMed ID: 16026708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
    Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiolabeling of phosphatidylserine-binding peptides with prosthetic groups N-[6-(4-[18F]fluorobenzylidene)aminooxyhexyl]maleimide ([18F]FBAM) and N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB).
    Kapty J; Kniess T; Wuest F; Mercer JR
    Appl Radiat Isot; 2011 Sep; 69(9):1218-25. PubMed ID: 21571539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Targeted α- and β
    Puttemans J; Dekempeneer Y; Eersels JL; Hanssens H; Debie P; Keyaerts M; Windhorst AD; van der Aa F; Lecocq Q; Breckpot K; Morgenstern A; Bruchertseifer F; Lahoutte T; Devoogdt N; D'Huyvetter M
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
    Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
    Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
    Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.
    Kramer-Marek G; Kiesewetter DO; Capala J
    J Nucl Med; 2009 Jul; 50(7):1131-9. PubMed ID: 19525458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (18)F-Labeled phosphopeptide-cell-penetrating peptide dimers with enhanced cell uptake properties in human cancer cells.
    Richter S; Bouvet V; Wuest M; Bergmann R; Steinbach J; Pietzsch J; Neundorf I; Wuest F
    Nucl Med Biol; 2012 Nov; 39(8):1202-12. PubMed ID: 22784382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate and application to (18)F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography.
    Johnström P; Clark JC; Pickard JD; Davenport AP
    Nucl Med Biol; 2008 Aug; 35(6):725-31. PubMed ID: 18678359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.